Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Dominique D DavisZahava OhanaHuy M PhamPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Pirtobrutinib has demonstrated safety and efficacy in heavily pre-treated adult patients with r/r MCL. Advantages of this drug include its usage in patients whose malignancy is resistant to current BTKi, tolerability, and response rate. Multiple clinical trials are underway to determine the efficacy of pirtobrutinib in other B-cell malignancies
Keyphrases
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute lymphoblastic leukemia
- open label
- acute myeloid leukemia
- prognostic factors
- peritoneal dialysis
- tyrosine kinase
- diffuse large b cell lymphoma
- emergency department
- patient reported outcomes
- double blind
- adverse drug